Somatostatin-dopamine ligands in the treatment of pituitary adenomas

Reviews in Endocrine and Metabolic Disorders

Volumn 10, Issue 2, 2009, Pages 83-90

  Saveanu, Alexandru ^a   Jaquet, Philippe ^a  

^a University of Mediterranée   (France)

Author keywords

BIM 23A387; BIM 23A760; Chimeric ligands; Dopamine receptors; Pituitary adenomas; Somatostatin receptors

Indexed keywords

ANGIOPEPTIN; BIM 23244; BIM 23268; BIM 23926; BIM 23A387; BIM 23A760; BIM 23A761; BIM 23A765; BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPASTATIN; GROWTH HORMONE; HORMONE RECEPTOR STIMULATING AGENT; L 054522; LIGAND; OCTREOTIDE; PASIREOTIDE; PROLACTIN; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ACROMEGALY; ACTH SECRETING ADENOMA; ADENOMA; CANCER INHIBITION; CUSHING ADENOMA; DIMERIZATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; GONADOTROPHINOMA; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HYPOPHYSIS ADENOMA; MIXED TUMOR; NONFUNCTIONING PITUITARY ADENOMA; NONHUMAN; PHARMACOPHORE; PROLACTINOMA; PROTEIN EXPRESSION; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; PITUITARY NEOPLASMS; RECEPTORS, DOPAMINE D2; RECEPTORS, SOMATOSTATIN;

EID: 67349160224     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11154-008-9086-0     Document Type: Review

References (72)

1. JC Reubi B Waser JC Schaer JA Laissue 2001 Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands Eur J Nucl Med 28 836 846 (Pubitemid 32662546)
2. YC Patel 1999 Somatostatin and its receptor family Front Neuroendocrinol 20 157 198 (Pubitemid 29362641)
3. L Stefaneanu K Kovacs E Horvath M Buchfelder R Fahlbusch L Lancranjan 2001 Dopamine D2 receptor gene expression in human adenohypophysial adenomas Endocrine 14 329 336 (Pubitemid 32547815)
4. JS Bevan J Webster CW Burke MF Scanlon 1992 Dopamine agonists and pituitary tumor shrinkage Endocr Rev 13 220 240
5. PU Freda 2002 Somatostatin analogs in acromegaly J Clin Endocrinol Metab 87 3013 3018
6. JC Reubi 2003 Peptide receptors as molecular targets for cancer diagnosis and therapy Endocr Rev 24 389 427 (Pubitemid 37056239)
7. GF Taboada RM Luque W Bastos RF Guimaraes JB Marcondes LM Chimelli 2007 Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas Eur J Endocrinol 156 65 74 (Pubitemid 46553904)
8. P Jaquet A Saveanu G Gunz F Fina AJ Zamora M Grino 2000 Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes J Clin Endocrinol Metab 85 781 792 (Pubitemid 32273669)
9. I Shimon X Yan JE Taylor MH Weiss MD Culler S Melmed 1997 Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors J Clin Invest 100 2386 2392 (Pubitemid 27500164)
10. MC Zatelli D Piccin F Tagliati MR Ambrosio A Margutti R Padovani 2003 Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion J Clin Endocrinol Metab 88 2797 2802 (Pubitemid 36724458)
11. P Jaquet L Ouafik A Saveanu G Gunz F Fina H Dufour 1999 Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas J Clin Endocrinol Metab 84 3268 3276 (Pubitemid 30646955)
12. A Saveanu I Morange-Ramos G Gunz H Dufour A Enjalbert P Jaquet 2001 A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies Eur J Endocrinol 145 35 41 (Pubitemid 32677674)
13. LJ Hofland J van der Hoek R Feelders MO van Aken PM van Koetsveld M Waaijers 2005 The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5 Eur J Endocrinol 152 645 654 (Pubitemid 40575811)
14. J van der Hoek M Waaijers PM van Koetsveld D Sprij-Mooij RA Feelders HA Schmid 2005 Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells Am J Physiol Endocrinol Metab 289 E278 E287 (Pubitemid 41076629)
15. DL Batista X Zhang R Gejman PJ Ansell Y Zhou SA Johnson 2006 The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas J Clin Endocrinol Metab 91 4482 4488
16. J Bertherat T Brue A Enjalbert G Gunz R Rasolonjanahary A Warnet 1992 Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions J Clin Endocrinol Metab 75 540 546
17. J van der Hoek WW de Herder RA Feelders AJ van der Lely P Uitterlinden V Boerlin 2004 A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients J Clin Endocrinol Metab 89 638 645 (Pubitemid 38269871)
18. D Ferone W de Herder R Pivonello J Kros P van Koetsfeld T de Jong 2008 Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy J Clin Endocrinol Metab 93 1412 1417
19. A Fusco G Gunz P Jaquet A-L Germanetti H Dufour MD Culler 2008 Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas Eur J Endocrinol 158 595 603
20. A Saveanu G Gunz H Dufour P Caron F Fina L Ouafik 2001 Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas J Clin Endocrinol Metab 86 140 145 (Pubitemid 32109787)
21. T Florio S Thellung S Arena A Corsaro R Spaziante G Gussoni 1999 Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro Eur J Endocrinol 141 396 408 (Pubitemid 29529495)
22. U Renner J Mojto M Lange OA Muller K von Werder GK Stalla 1994 Effect of bromocriptine and SMS 201-995 on growth of human somatotrophic and non-functioning pituitary adenoma cells in vitro Eur J Endocrinol 130 80 91 (Pubitemid 24110437)
23. MC Zatelli D Piccin A Bottoni MR Ambrosio A Margutti R Padovani 2004 Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro J Clin Endocrinol Metab 89 5181 5188 (Pubitemid 39391467)
24. Y Greenman S Melmed 1994 Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors J Clin Endocrinol Metab 78 398 403 (Pubitemid 24061760)
25. TW de Bruin DJ Kwekkeboom JW Van't Verlaat JC Reubi EP Krenning SW Lamberts 1992 Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro J Clin Endocrinol Metab 75 1310 1317
26. L Katznelson DS Oppenheim JF Coughlin B Kliman DA Schoenfeld A Klibanski 1992 Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors J Clin Endocrinol Metab 75 1318 1325
27. MZ Strowski M Kohler HY Chen ME Trumbauer Z Li D Szalkowski 2003 Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis Mol Endocrinol 17 93 106 (Pubitemid 36132661)
28. HV Socin P Chanson B Delemer A Tabarin V Rohmer J Mockel 2003 The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients Eur J Endocrinol 148 433 442 (Pubitemid 36527414)
29. A Liuzzi PG Chiodini L Botalla G Cremascoli F Silvestrini 1972 Inhibitory effect of l-Dopa on GH release in acromegalic patients J Clin Endocrinol Metab 35 941 943
30. R Abs J Verhelst D Maiter K Van Acker F Nobels JL Coolens 1998 Cabergoline in the treatment of acromegaly: a study in 64 patients J Clin Endocrinol Metab 83 374 378 (Pubitemid 28496509)
31. R Cozzi R Attanasio M Barausse D Dallabonzana P Orlandi N Da Re 1998 Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 139 516 521 (Pubitemid 28539706)
32. P Marzullo D Ferone C Di Somma R Pivonello M Filippella G Lombardi 1999 Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients Pituitary 1 115 120
33. R Pivonello D Ferone WW de Herder JM Kros ML De Caro M Arvigo 2004 Dopamine receptor expression and function in corticotroph pituitary tumors J Clin Endocrinol Metab 89 2452 2462 (Pubitemid 38619889)
34. Y Greenman K Tordjman E Osher I Veshchev G Shenkerman G Reider II 2005 Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth Clin Endocrinol (Oxf) 63 39 44 (Pubitemid 40966400)
35. A Colao D Ferone S Lastoria G Cerbone A Di Sarno C Di Somma 2000 Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide Clin Endocrinol (Oxf) 52 437 445 (Pubitemid 30249811)
36. T Lohmann C Trantakis M Biesold S Prothmann S Guenzel R Schober 2001 Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline Pituitary 4 173 178 (Pubitemid 34679333)
37. R Pivonello C Matrone M Filippella LM Cavallo C Di Somma P Cappabianca 2004 Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment J Clin Endocrinol Metab 89 1674 1683 (Pubitemid 38507920)
38. I Pellegrini R Rasolonjanahary G Gunz P Bertrand S Delivet CP Jedynak 1989 Resistance to bromocriptine in prolactinomas J Clin Endocrinol Metab 69 500 509 (Pubitemid 19221218)
39. SG Ren J Taylor J Dong R Yu MD Culler S Melmed 2003 Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion J Clin Endocrinol Metab 88 4239 4245 (Pubitemid 37153726)
40. A Saveanu E Lavaque G Gunz A Barlier S Kim JE Taylor 2002 Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells J Clin Endocrinol Metab 87 5545 5552 (Pubitemid 36034358)
41. SG Ren S Kim J Taylor J Dong JP Moreau MD Culler 2003 Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/ dopaminergic chimeric ligand J Clin Endocrinol Metab 88 5414 5421 (Pubitemid 37452747)
42. P Jaquet G Gunz A Saveanu H Dufour J Taylor J Dong 2005 Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy Eur J Endocrinol 153 135 141 (Pubitemid 41030524)
43. L Yang L Guo A Pasternak R Mosley S Rohrer E Birzin 1998 Spiro[1H-indene-1,4-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst2) agonists J Med Chem 41 2175 2179 (Pubitemid 28285717)
44. A Saveanu G Gunz S Guillen H Dufour MD Culler P Jaquet 2006 Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas Neuroendocrinology 83 258 263 (Pubitemid 44578880)
45. M Rocheville DC Lange U Kumar SC Patel RC Patel YC Patel 2000 Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity Science 288 154 157 (Pubitemid 30203051)
46. A Gruszka J Kunert-Radek A Radek H Pisarek J Taylor JZ Dong 2006 The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro Life Sci 78 689 693 (Pubitemid 41821125)
47. D Ferone M Arvigo C Semino P Jaquet A Saveanu JE Taylor 2005 Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation Am J Physiol Endocrinol Metab 289 E1044 E1050 (Pubitemid 43671055)
48. M Kidd IM Modlin JW Black M Boyce M Culler 2007 A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation Regul Pept 143 109 117 (Pubitemid 47212532)
49. U Plockinger S Albrecht C Mawrin W Saeger M Buchfelder S Petersenn 2008 Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas J Clin Endocrinol Metab 93 1203 1210
50. JC Schaer B Waser G Mengod JC Reubi 1997 Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography Int J Cancer 70 530 537 (Pubitemid 27149636)
51. LJ Hofland SW Lamberts PM van Hagen JC Reubi J Schaeffer M Waaijers 2003 Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs J Nucl Med 44 1315 1321 (Pubitemid 39655192)
52. A Barlier I Pellegrini-Bouiller L Caccavelli G Gunz I Morange-Ramos P Jaquet 1997 Abnormal transduction mechanisms in pituitary adenomas Horm Res 47 227 234 (Pubitemid 27196457)
53. RC Patel U Kumar DC Lamb JS Eid M Rocheville M Grant 2002 Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells Proc Natl Acad Sci USA 99 3294 3299 (Pubitemid 34240625)
54. M Grant RC Patel U Kumar 2004 The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors J Biol Chem 279 38636 38643 (Pubitemid 39296019)
55. D Armstrong PG Strange 2001 Dopamine D2 receptor dimer formation: evidence from ligand binding J Biol Chem 276 22621 22629 (Pubitemid 37410944)
56. GY Ng BF O'Dowd SP Lee HT Chung MR Brann P Seeman 1996 Dopamine D2 receptor dimers and receptor-blocking peptides Biochem Biophys Res Commun 227 200 204 (Pubitemid 26370576)
57. A Baragli H Alturaihi HL Watt A Abdallah U Kumar 2007 Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis Cell Signal 19 2304 2316 (Pubitemid 47361686)
58. S Bulenger S Marullo M Bouvier 2005 Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation Trends Pharmacol Sci 26 131 137 (Pubitemid 40313592)
59. SR George BF O'Dowd SP Lee 2002 G-protein-coupled receptor oligomerization and its potential for drug discovery Nat Rev Drug Discov 1 808 820 (Pubitemid 37361564)
60. S Terrillon M Bouvier 2004 Roles of G-protein-coupled receptor dimerization EMBO Rep 5 30 34 (Pubitemid 38228524)
61. CB Brink BH Harvey J Bodenstein DP Venter DW Oliver 2004 Recent advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology Br J Clin Pharmacol 57 373 387 (Pubitemid 38519641)
62. S Maudsley B Martin LM Luttrell 2005 The origins of diversity and specificity in G protein-coupled receptor signaling J Pharmacol Exp Ther 314 485 494 (Pubitemid 41043828)
63. RS Ostrom SR Post PA Insel 2000 Stoichiometry and compartmentation in G protein-coupled receptor signaling: implications for therapeutic interventions involving G(s) J Pharmacol Exp Ther 294 407 412 (Pubitemid 30490809)
64. LJ Hofland SW Lamberts 2003 The pathophysiological consequences of somatostatin receptor internalization and resistance Endocr Rev 24 28 47 (Pubitemid 36223278)
65. G Tulipano R Stumm M Pfeiffer HJ Kreienkamp V Hollt S Schulz 2004 Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes J Biol Chem 279 21374 21382 (Pubitemid 38656546)
66. Y Hakak D Shrestha MC Goegel DP Behan DT Chalmers 2003 Global analysis of G-protein-coupled receptor signaling in human tissues FEBS Lett 550 11 17 (Pubitemid 37281349)
67. M Pfeiffer T Koch H Schroder M Laugsch V Hollt 2002 Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization J Biol Chem 277 19762 19772
68. M Canals D Marcellino F Fanelli F Ciruela P de Benedetti SR Goldberg 2003 Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer J Biol Chem 278 46741 46749 (Pubitemid 37452253)
69. M Rocheville DC Lange U Kumar R Sasi RC Patel YC Patel 2000 Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers J Biol Chem 275 7862 7869 (Pubitemid 30159693)
70. M Pfeiffer T Koch H Schroder M Klutzny S Kirscht HJ Kreienkamp 2001 Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst (3) receptor function by heterodimerization with sst (2A) J Biol Chem 276 14027 14036 (Pubitemid 37391786)
71. A Ben-Shlomo O Pichurin NJ Barshop KA Wawrowsky J Taylor MD Culler 2007 Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation Mol Endocrinol 21 2565 2578 (Pubitemid 47529366)
72. HL Watt U Kumar 2006 Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells Cancer Cell Int 6 5 (Pubitemid 43885011)